Disparities in receipt of care for high-grade endometrial cancer: A National Cancer Data Base analysis

Gynecologic Oncology

Volumn 145, Issue 1, 2017, Pages 114-121

  Bregar, Amy J ^a   Alejandro Rauh Hain, J ^a   Spencer, Ryan ^b   Clemmer, Joel T ^a   Schorge, John O ^a   Rice, Laurel W ^b   del Carmen, Marcela G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER CHEMOTHERAPY; CARCINOSARCOMA; CLEAR CELL CARCINOMA; COMORBIDITY; EDUCATIONAL STATUS; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FEMALE; HISPANIC; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RACE DIFFERENCE; SOCIAL STATUS; ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, PAPILLARY; ADJUVANT CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CARCINOMA, ENDOMETRIOID; CAUCASIAN; CAUSE OF DEATH; EDUCATION; ENDOMETRIAL NEOPLASMS; ETHNIC GROUP; ETHNOLOGY; FACTUAL DATABASE; HEALTH CARE DISPARITY; HYSTERECTOMY; INSURANCE; MORTALITY; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; PATHOLOGY; RETROSPECTIVE STUDY; SOCIAL CLASS; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; UNITED STATES;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, PAPILLARY; AFRICAN AMERICANS; AGED; CARCINOMA, ENDOMETRIOID; CARCINOSARCOMA; CAUSE OF DEATH; CHEMOTHERAPY, ADJUVANT; COMORBIDITY; DATABASES, FACTUAL; EDUCATION; ENDOMETRIAL NEOPLASMS; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTHCARE DISPARITIES; HISPANIC AMERICANS; HUMANS; HYSTERECTOMY; INSURANCE COVERAGE; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SOCIAL CLASS; SURVIVAL RATE; UNITED STATES;

EID: 85011101276     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2017.01.024     Document Type: Article

References (50)

1. [1] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J. Clin. 66 (2016), 7–30.
2. [2] Acharya, S., Hensley, M.L., Montag, A.C., Fleming, G.F., Rare uterine cancers. Lancet Oncol. 6 (2005), 961–971.
3. [3] Hicks, M.L., Phillips, J.L., Parham, G., Andrews, N., Jones, W.B., Shingleton, H.M., et al. The National Cancer Data Base report on endometrial carcinoma in African-American women. Cancer 83 (1998), 2629–2637.
4. [4] Setiawan, V.W., Pike, M.C., Kolonel, L.N., Nomura, A.M., Goodman, M.T., Henderson, B.E., Racial/ethnic differences in endometrial cancer risk: the multiethnic cohort study. Am. J. Epidemiol. 165 (2007), 262–270.
5. [5] Sherman, M.E., Devesa, S.S., Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer 98 (2003), 176–186.
6. [6] Smotkin, D., Nevadunsky, N.S., Harris, K., Einstein, M.H., Yu, Y., Goldberg, G.L., Histopathologic differences account for racial disparity in uterine cancer survival. Gynecol. Oncol. 127 (2012), 616–619.
7. [7] Cook, L.S., Nelson, H.E., Cockburn, M., Olson, S.H., Muller, C.Y., Wiggins, C.L., Comorbidities and endometrial cancer survival in Hispanics and non-Hispanic whites. Cancer Causes Control 24 (2013), 61–69.
8. [8] NA, Howlader N., Krapcho, M., Garshell, J., Miller, D., Altekruse, S.F., Kosary, C.L., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., Lewis, D.R., Chen, H.S., Feuer, E.J., Cronin, K.A., (eds.) SEER Cancer Statistics Review, 1975–2012, April 2015, National Cancer Institute, Bethesda, MD (Available: http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER data submission, posted to the SEER web site).
9. [9] Wright, J.D., Fiorelli, J., Schiff, P.B., Burke, W.M., Kansler, A.L., Cohen, C.J., et al. Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time. Cancer 115 (2009), 1276–1285.
10. [10] Cote, M.L., Ruterbusch, J.J., Olson, S.H., Lu, K., Ali-Fehmi, R., The growing burden of endometrial cancer: a major racial disparity affecting black women. Cancer Epidemiol. Biomark. Prev. 24 (2015), 1407–1415.
11. [11] Hill, H.A., Eley, J.W., Harlan, L.C., Greenberg, R.S., Barrett, R.J. 2nd, Chen, V.W., Racial differences in endometrial cancer survival: the black/white cancer survival study. Obstet. Gynecol. 88 (1996), 919–926.
12. [12] Olson, S.H., Atoria, C.L., Cote, M.L., Cook, L.S., Rastogi, R., Soslow, R.A., et al. The impact of race and comorbidity on survival in endometrial cancer. Cancer Epidemiol. Biomark. Prev. 21 (2012), 753–760.
13. [13] Schiff, M., Key, C.R., Gilliland, F.D., Becker, T.M., Ethnic differences in uterine corpus cancer incidence and mortality in New Mexico's American Indians, hispanics and non-Hispanic whites. Int. J. Epidemiol. 26 (1997), 249–255.
14. [14] Mahdi, H., Hou, H., Kowk, L.L., Moslemi-Kebria, M., Michener, C., Type II endometrial cancer in Hispanic women: tumor characteristics, treatment and survival compared to non-Hispanic white women. Gynecol. Oncol. 133 (2014), 512–517.
15. [15] Rodriguez, A.M., Schmeler, K.M., Kuo, Y.F., Disparities in endometrial cancer outcomes between non-Hispanic White and Hispanic women. Gynecol. Oncol. 135 (2014), 525–533.
16. [16] Rauh-Hain, J.A., Buskwofie, A., Clemmer, J., Boruta, D.M., Schorge, J.O., del Carmen, M.G., Racial disparities in treatment of high-grade endometrial cancer in the Medicare population. Obstet. Gynecol. 125 (2015), 843–851.
17. [17] Office of Management and Budget, Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity. Federal Register Notice. 1997.
18. [18] Siegel, R.L., Fedewa, S.A., Miller, K.D., Goding-Sauer, A., Pinheiro, P.S., Martinez-Tyson, D., et al. Cancer statistics for Hispanics/Latinos, 2015. CA Cancer J. Clin. 65 (2015), 457–480.
19. [19] Aragones, A., Hayes, S.L., Chen, M.H., Gonzalez, J., Gany, F.M., Characterization of the Hispanic or latino population in health research: a systematic review. J. Immigr. Minor. Health 16 (2014), 429–439.
20. [20] Raval, M.V., Bilimoria, K.Y., Stewart, A.K., Bentrem, D.J., Ko, C.Y., Using the NCDB for cancer care improvement: an introduction to available quality assessment tools. J. Surg. Oncol. 99 (2009), 488–490.
21. [21] Howe, J.R., Karnell, L.H., Menck, H.R., Scott-Conner, C., The American College of Surgeons Commission on cancer and the American Cancer Society. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985–1995. Cancer 86 (1999), 2693–2706.
22. [22] Koshy, M., Fedewa, S.A., Malik, R., Ferguson, M.K., Vigneswaran, W.T., Feldman, L., et al. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer. J. Thorac. Oncol. 8 (2013), 915–922.
23. [23] Ganapathi, A.M., Speicher, P.J., Englum, B.R., Castleberry, A.W., Migaly, J., Hsu, D.S., et al. Adjuvant chemotherapy for t1 node-positive colon cancers provides significant survival benefit. Dis. Colon Rectum 57 (2014), 1341–1348.
24. [24] Rueth, N.M., Lin, H.Y., Bedrosian, I., Shaitelman, S.F., Ueno, N.T., Shen, Y., et al. Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database. J. Clin. Oncol. 32 (2014), 2018–2024.
25. [25] American College of Surgeons National Cancer Data Base Participant User File. Available: http://ncdbpuf.facs.org/node/259?q=print-pdf-all [accessed December 15, 2016].
26. [26] Rungruang, B., Olawaiye, A.B., Comprehensive surgical staging for endometrial cancer. Q. Rev. Obstet. Gynecol. 5 (2012), 28–34.
27. [27] United States Departement of Agriculture Economic Research Services: Rural Urban Continuum Codes. Available: http://www.ers.usda.gov/data-products/rural-urban-continuum-codes.aspx [accessed December 15, 2016].
28. [28] Klabunde, C.N., Potosky, A.L., Legler, J.M., Warren, J.L., Development of a comorbidity index using physician claims data. J. Clin. Epidemiol. 53 (2000), 1258–1267.
29. [29] Charlson, M.E., Pompei, P., Ales, K.L., MacKenzie, C.R., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40 (1987), 373–383.
30. [30] Clifford, S.L., Kaminetsky, C.P., Cirisano, F.D., Dodge, R., Soper, J.T., Clarke-Pearson, D.L., et al. Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer. Am. J. Obstet. Gynecol. 176 (1997), S229–S232.
31. [31] Kohler, M.F., Berchuck, A., Davidoff, A.M., Humphrey, P.A., Dodge, R.K., Iglehart, J.D., et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res. 52 (1992), 1622–1627.
32. [32] Maxwell, G.L., Risinger, J.I., Hayes, K.A., Alvarez, A.A., Dodge, R.K., Barrett, J.C., et al. Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers. Clin. Cancer Res. 6 (2000), 2999–3005.
33. [33] Santin, A.D., Bellone, S., Siegel, E.R., Palmieri, M., Thomas, M., Cannon, M.J., et al. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am. J. Obstet. Gynecol. 192 (2005), 813–818.
34. [34] Sutton, J., Orloff, M.S., Michener, C., Chiesa-Vottero, A., Prayson, R., Nowacki, A.S., et al. Association of specific PTEN/10q haplotypes with endometrial cancer phenotypes in African-American and European American women. Gynecol. Oncol. 138 (2015), 434–440.
35. [35] Rocconi, R.P., Lankes, H.A., Brady, W.E., Goodfellow, P.J., Ramirez, N.C., Alvarez, R.D., et al. The role of racial genetic admixture with endometrial cancer outcomes: an NRG Oncology/Gynecologic Oncology Group study. Gynecol. Oncol. 140 (2016), 264–269.
36. [36] Rogers, R.G., Crimmins, E.M., International Handbook of Adult Mortality. Dordrecht Netherlands. 2011, Springer, New York.
37. [37] Baker, D.P., Leon, J., Smith Greenaway, E.G., Collins, J., Movit, M., The education effect on population health: a reassessment. Popul. Dev. Rev. 37 (2011), 307–332.
38. [38] Elo, I.T., Social class differentials in health and mortality: patterns and explanations in comparative perspective. Annu. Rev. Sociol. 35 (2009), 553–572.
39. [39] Lariscy, J.T., Nau, C., Firebaugh, G., Hummer, R.A., Hispanic-white differences in lifespan variability in the United States. Demography 53 (2016), 215–239.
40. [40] Edwards, R.D., The cost of uncertain life span. J. Popul. Econ., 2008, w14093.
41. [41] Arias, E., National Center for Health Statistics (U.S.). The Validity of Race and Hispanic Origin Reporting on Death Certificates in the United States: Data Evaluation and Methods Research. 2008, U.S. Department of Health and Human Services/Centers for Disease Control and Prevention/National Center for Health Statistics, Hyattsville, MD.
42. [42] Turra, C.M., Elo, I.T., The impact of salmon bias on the Hispanic mortality advantage: new evidence from social security data. Popul. Res. Policy Rev. 27 (2008), 515–530.
43. [43] Madison, T., Schottenfeld, D., James, S.A., Schwartz, A.G., Gruber, S.B., Endometrial cancer: socioeconomic status and racial/ethnic differences in stage at diagnosis, treatment, and survival. Am. J. Public Health 94 (2004), 2104–2111.
44. [44] Maxwell, G.L., Tian, C., Risinger, J., Brown, C.L., Rose, G.S., Thigpen, J.T., et al. Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer 107 (2006), 2197–2205.
45. [45] Perez-Stable, E.J., Sabogal, F., Otero-Sabogal, R., Hiatt, R.A., McPhee, S.J., Misconceptions about cancer among Latinos and Anglos. JAMA 268 (1992), 3219–3223.
46. [46] Womeodu, R.J., Bailey, J.E., Barriers to cancer screening. Med. Clin. North Am. 80 (1996), 115–133.
47. [47] Eloubeidi, M.A., Desmond, R.A., Wilcox, C.M., Wilson, R.J., Manchikalapati, P., Fouad, M.M., et al. Prognostic factors for survival in pancreatic cancer: a population-based study. Am. J. Surg. 192 (2006), 322–329.
48. [48] Mahdi, H., Lockhart, D., Moslemi-Kebria, M., Rose, P.G., Racial disparity in the 30-day morbidity and mortality after surgery for endometrial cancer. Gynecol. Oncol. 134 (2014), 510–515.
49. [49] Cote, M.L., Ruterbusch, J.J., Ahmed, Q., Bandyopadhyay, S., Alosh, B., Abdulfatah, E., et al. Endometrial cancer in morbidly obese women: do racial disparities affect surgical or survival outcomes?. Gynecol. Oncol. 133 (2014), 38–42.
50. [50] Ruterbusch, J.J., Ali-Fehmi, R., Olson, S.H., Sealy-Jefferson, S., Rybicki, B.A., Hensley-Alford, S., et al. The influence of comorbid conditions on racial disparities in endometrial cancer survival. Am. J. Obstet. Gynecol. 211:627 (2014), e1–e9.